연구동향 분석

Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors

오도연 이세훈 한세원 김미정 김태민 김태유 허대석 Miyuki Yuasa Yasuo Yanagihara 방영주 2015년

논문상세정보
인용/피인용
' Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • opb-31121
  • phase i
  • solid tumor
  • stat3
  • stat3 inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,350 0

0.0%

' Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors' 의 참고문헌

  • Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
    Calvisi DF Gastroenterology 130 : 1117 ~ 1128 [2006]
  • Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
    Calvisi DF Gastroenterology 130 1117-1128 [2006]
  • Therapeutic potential of JAK2 inhibitors
    Verstovsek S. Hematology Am Soc Hematol Educ Program : 636 ~ 642 [2009]
  • Therapeutic potential of JAK2 inhibitors
    Verstovsek S. Hematology Am Soc Hematol Educ Program 636-642 [2009]
  • The STATs of cancer : new molecular targets come of age
    Yu H Nat Rev Cancer 4 : 97 ~ 105 [2004]
  • The STATs of cancer : new molecular targets come of age
    Yu H Nat Rev Cancer 4 97-105 [2004]
  • Targeting the interleukin-6/Jak/stat pathway in human malignancies
    Sansone P J Clin Oncol 30 : 1005 ~ 1014 [2012]
  • Targeting the interleukin-6/Jak/stat pathway in human malignancies
    Sansone P J Clin Oncol 30 1005-1014 [2012]
  • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    Alvarez JV Cancer Res 66 : 3162 ~ 3168 [2006]
  • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
    Alvarez JV Cancer Res 66 3162-3168 [2006]
  • Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II)by anti-interleukin 6monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody
    Mizutani Y Cancer Res 55 : 590 ~ 596 [1995]
  • Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II)by anti-interleukin 6monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody
    Mizutani Y Cancer Res 55 590-596 [1995]
  • STATs in cancer inflammation and immunity: a leading role for STAT3
    Yu H Nat Rev Cancer 9 798-809 [2009]
  • STATs in cancer inflammation and immunity : a leading role for STAT3
    Yu H Nat Rev Cancer 9 : 798 ~ 809 [2009]
  • STAT3 is necessary for proliferation and survival in colon cancer-initiating cells
    Lin L Cancer Res 71 : 7226 ~ 7237 [2011]
  • STAT3 is necessary for proliferation and survival in colon cancer-initiating cells
    Lin L Cancer Res 71 7226-7237 [2011]
  • STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
    Morikawa T Clin Cancer Res 17 : 1452 ~ 1462 [2011]
  • STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers
    Morikawa T Clin Cancer Res 17 1452-1462 [2011]
  • STAT3 : a multifaceted oncogene
    Levy DE Proc Natl Acad Sci U S A 103 : 10151 ~ 10152 [2006]
  • STAT3 : a multifaceted oncogene
    Levy DE Proc Natl Acad Sci U S A 103 10151-10152 [2006]
  • STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer
    Deng JY World J Gastroenterol 16 : 5380 ~ 5387 [2010]
  • STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer
    Deng JY World J Gastroenterol 16 5380-5387 [2010]
  • Preface : STAT signaling
    Jove R Oncogene 19 : 2466 ~ 2467 [2000]
  • Preface : STAT signaling
    Jove R Oncogene 19 2466-2467 [2000]
  • Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell JC Cancer Chemother Pharmacol 74 : 125 ~ 130 [2014]
  • Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
    Bendell JC Cancer Chemother Pharmacol 74 125-130 [2014]
  • OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
    Kim MJ Cancer Lett 335 : 145 ~ 152 [2013]
  • OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells
    Kim MJ Cancer Lett 335 145-152 [2013]
  • Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors
    Motte N Int J Cancer 121 : 2113 ~ 2115 [2007]
  • Mutations in JAK2V617F homologous domain of JAK genes are uncommon in solid tumors
    Motte N Int J Cancer 121 2113-2115 [2007]
  • Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3
    Li WC Clin Cancer Res 12 : 7140 ~ 7148 [2006]
  • Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3
    Li WC Clin Cancer Res 12 7140-7148 [2006]
  • Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis
    Alas S Clin Cancer Res 9 : 316 ~ 326 [2003]
  • Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis
    Alas S Clin Cancer Res 9 316-326 [2003]
  • Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer
    Chen J Mol Cancer Ther 11 : 277 ~ 287 [2012]
  • Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer
    Chen J Mol Cancer Ther 11 277-287 [2012]
  • Inhibiting signal transducer and activator of transcription 3 : rationality and rationale design of inhibitors
    Mankan AK Expert Opin Investig Drugs 20 : 1263 ~ 1275 [2011]
  • Inhibiting signal transducer and activator of transcription 3 : rationality and rationale design of inhibitors
    Mankan AK Expert Opin Investig Drugs 20 1263-1275 [2011]
  • Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer
    Gong W Clin Cancer Res 11 : 1386 ~ 1393 [2005]
  • Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer
    Gong W Clin Cancer Res 11 1386-1393 [2005]
  • Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
    Grandis JR Proc Natl Acad Sci U S A 97 : 4227 ~ 4232 [2000]
  • Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo
    Grandis JR Proc Natl Acad Sci U S A 97 4227-4232 [2000]
  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine RL Cancer Cell 7 : 387 ~ 397 [2005]
  • Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
    Levine RL Cancer Cell 7 387-397 [2005]
  • Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter EJ Lancet 365 : 1054 ~ 1061 [2005]
  • Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
    Baxter EJ Lancet 365 1054-1061 [2005]
  • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    James C Nature 434 : 1144 ~ 1148 [2005]
  • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    James C Nature 434 1144-1148 [2005]
  • A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics R N Engl J Med 352 : 1779 ~ 1790 [2005]
  • A gain-of-function mutation of JAK2 in myeloproliferative disorders
    Kralovics R N Engl J Med 352 1779-1790 [2005]